How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

Draft guidance consultation

Open for comments Open until   Request commenting lead permission

We have updated this service so that members of the same organisation can now collaborate on a joint online response.

Read our blog to learn more.

2 Information about glofitamab with gemcitabine and oxaliplatin

Marketing authorisation indication

2.1

Glofitamab (Columvi, Roche) in combination with gemcitabine and oxaliplatin is indicated for 'the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified who are ineligible for autologous stem cell transplant'.

Dosage in the marketing authorisation

Price

2.3

The list price for glofitamab is £687 per 2.5‑mg vial and £2,748 per 10‑mg vial (excluding VAT, BNF online, accessed July 2025).

2.4

The list price for gemcitabine is £14 per 200‑mg vial of powder for solution for infusion and £25 per 1000‑mg vial of powder for solution for infusion (excluding VAT, BNF online, accessed July 2025).

2.5

The list price for oxaliplatin is £147.82 per 50 mg (10 ml) vial of concentrate for solution for infusion and £295.63 per 100 mg (20 ml) vial of concentrate for solution for infusion (excluding VAT, BNF online, accessed July 2025).

2.6

The company has a commercial arrangement. This makes glofitamab available to the NHS with a discount and it would have also applied to this indication if glofitamab with gemcitabine and oxaliplatin had been recommended. The size of the discount is commercial in confidence.

Carbon Reduction Plan

2.7

Information on the Carbon Reduction Plan for UK carbon emissions for Roche will be included here when guidance is published.